Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou're about to book a holiday and wondering whether Mounjaro — tirzepatide, the once-weekly weight-loss injection — needs to be declared to your travel insurer. The short answer: yes, in most cases it does, because it is a prescription medicine for an ongoing health condition, and most UK travel insurers require you to disclose pre-existing medical conditions and the medications prescribed for them. Exactly what you need to declare, and how your insurer responds, depends entirely on your individual policy and provider. As a prescription-only medicine requiring clinical assessment, Mounjaro can only be obtained through a qualified prescriber, and your prescriber or GP is a good first port of call if you need a summary of your medical history to share with an insurer.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: flights booked, hotel confirmed, and then you get to the travel insurance form. There's a section asking about prescription medicines and pre-existing health conditions. Mounjaro sits squarely in both categories. Tirzepatide is prescribed for weight management (and in some cases type 2 diabetes), and both of those are conditions that UK insurers treat as pre-existing. Most policies define a pre-existing condition as any condition for which you have received treatment, advice, or medication in the months or years before you buy the policy, a current Mounjaro prescription fits that definition cleanly.
Skipping that disclosure to keep the premium down is a risk that regularly backfires. If you needed emergency hospital treatment abroad for a reason that your insurer could link to an undisclosed condition (say, severe nausea and dehydration, which can occur as a side effect of GLP-1 medicines) the insurer may refuse to pay out. The question of whether Mounjaro needs declaring and how to do it correctly is covered in detail on our guide to declaring Mounjaro on travel insurance, which walks through the standard UK insurer questions step by step.
The NHS's guidance on weight-management injections confirms that healthcare teams should be made aware of travel plans so that storage, supply and any timing adjustments can be considered, practical advice that applies equally to telling your insurer you're on treatment. See NHS England's weight-management injections guidance for the clinical context.
Declaring a prescription medicine doesn't automatically mean your cover is refused or that your premium triples. Outcomes vary widely between providers. Some insurers will note Mounjaro alongside the underlying condition, add a modest loading to the premium, and cover you fully. Others may exclude claims directly related to the medicine or the conditions it treats, while covering everything else at the standard rate. A few specialist medical travel insurers will cover the full picture without exclusions, particularly if your weight-related conditions are well managed.
What matters is accuracy. Be specific: name the medicine, name the conditions it's prescribed for, and give honest answers about any related symptoms you've experienced. If you are unsure how to describe your health situation to an insurer, your prescriber or GP can provide a brief summary letter. Some patients find it useful to contact insurers directly to ask how tirzepatide is coded on their system, it may appear under the brand name Mounjaro, the generic name tirzepatide, or under the condition category rather than the drug name.
For a comparison of how specific UK providers treat Mounjaro declarations, the Admiral travel insurance and Mounjaro page looks at one commonly used insurer in detail. For broader information about what coverage options generally look like, our overview of Mounjaro and travel insurance sets out the landscape.
Separate from the insurance question, travelling with Mounjaro pens takes a little preparation. Each KwikPen must be kept refrigerated at 2–8°C until you travel; once at room temperature, there is a limited window during which the pen remains usable, the exact duration is in the Patient Information Leaflet and varies, so read the leaflet before you pack rather than relying on memory or online estimates.
For the journey itself: keep pens in an insulated travel case with cooling packs, carry them in hand luggage rather than checked bags (hold temperatures are unpredictable), and bring your prescription documentation or a pharmacist's letter, particularly for travel outside the UK. Airports in Europe and beyond will generally let you carry injectable medicines once you can show a prescription or letter from a clinician.
Needles need to travel too. Used sharps should go into a sharps container (compact travel options are available) and you'll want to check local rules for disposing of them at your destination. Take enough pens for your full trip, plus a couple of days' buffer for delays. Running out abroad is stressful; the Mounjaro supply chain is UK-specific, so obtaining a replacement pen in another country is not straightforward. Our Mounjaro injection guide covers storage windows, site rotation and other practical injection questions in full.
If questions arise about dose timing while you're away (crossing time zones, an upset stomach affecting your usual routine) that's a conversation for your prescriber before you travel, not a decision to make at 35,000 feet. You can also read our step-by-step guide to adding Mounjaro to your travel insurance for guidance on getting that part of your preparation right before you leave. Our clinical team is reachable via our contact page if something comes up mid-trip.
One question our prescribers hear in the weeks before summer travel is whether patients should delay a dose increase until they're back. That's exactly the kind of question that belongs in a clinical conversation, not in a forum thread. If you're mid-treatment and planning travel, mention it at your next review; the prescriber can factor your trip into any recommendation about timing.
For people who haven't yet started treatment, the private route through a regulated online pharmacy means no referral wait and no long queue. A consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reads your answers. Once approved, the pen leaves our GPhC-registered pharmacy the same day (for orders placed before midday, Monday to Friday) and arrives via DPD the next working day in plain, unbranded packaging, with tracking sent to your phone.
Everything about the treatment, from consultation through prescription to delivery and 7-day aftercare, is included in a single transparent price, no hidden add-ons. You can see the full picture on the treatment options page. For context on what private Mounjaro treatment costs and what drives the pricing, the guide to obtaining Mounjaro through a registered UK pharmacy covers that ground honestly, including the MHRA's warnings about counterfeit pens sold outside the licensed supply chain.
Ready to get the clinical side sorted before your trip? Speak to our prescribers, the consultation is free, and the same-day review means you're not left waiting.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.